Copyright
©The Author(s) 2025.
World J Gastrointest Oncol. Jul 15, 2025; 17(7): 106684
Published online Jul 15, 2025. doi: 10.4251/wjgo.v17.i7.106684
Published online Jul 15, 2025. doi: 10.4251/wjgo.v17.i7.106684
Table 1 Demographic information and tumor characteristics of patients (n = 112), n (%)
| Characteristics | Treatment group (n = 58) | Control group (n = 54) | P value |
| WBC (109/L), mean ± SD | 6.87 ± 6.60 | 7.15 ± 4.44 | 0.796 |
| Neutrophil (109/L), mean ± SD | 66.26 ± 15.58 | 69.9 ± 14.86 | 0.209 |
| Lymphocyte (109/L), mean ± SD | 1.15 ± 0.41 | 0.98 ± 0.51 | 0.060 |
| Monocyte (109/L), mean ± SD | 0.64 ± 0.44 | 0.89 ± 1.74 | 0.309 |
| Age (year), mean ± SD | 63.98 ± 10.17 | 67.4 ± 11.91 | 0.097 |
| Sex | 0.056 | ||
| Male | 42 (72.4) | 7(13.0) | |
| Female | 16 (27.6) | 47(87.0) | |
| HBV | 0.054 | ||
| Yes | 18 (31) | 27 (50) | |
| No | 40 (69) | 27 (50) | |
| Child-Pugh grade | 0.076 | ||
| A | 45 (77.6) | 26 (48.1) | |
| B | 13 (22.4) | 28 (51.9) | |
| ECOG-PS | 0.249 | ||
| 0 | 12 (20.7) | 9 (16.7) | |
| 1 | 39 (67.2) | 32 (59.3) | |
| 2 | 7 (12.1) | 12 (24.1) | |
| Tumor size (cm) | 0.938 | ||
| ≥ 5 | 20 (34.5) | 19 (35.2) | |
| < 5 | 38 (65.5) | 35 (64.8) | |
| Lenvatinib/sorafenib treatment | 0.982 | ||
| Yes | 46 (79) | 43 (80) | |
| No | 12 (21) | 11(20) | |
- Citation: Zhu YF, Zhang DW, Zhang M, Yu MH, Zhang SH, Wu YY. Prognostic value of immune-inflammation and nutritional indices in advanced hepatocellular carcinoma patients receiving immunotherapy with compound Kushen injection. World J Gastrointest Oncol 2025; 17(7): 106684
- URL: https://www.wjgnet.com/1948-5204/full/v17/i7/106684.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v17.i7.106684